Soleno Therapeutics announces top-line results from phase III trial of DCCR for treatment of Prader-Willi syndrome.
Soleno Therapeutics, Inc. announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome… read more.